07/12/12Amarin shares plunge on decision to hire own sales force for Vascepa launch
14/11/11Amarin to present positive results from two phase 3 studies of anti-triglyceride drug
26/09/11Amarin submits NDA for triglyceride-lowering AMR101 drug
18/04/11Amarin shares surge on phase III results of triglyceride-lowering drug
Recent Sector News
Pressure BioSciences (OTCQB:PBIO) has shipped its third new Barozyme high throughput HT48 system to the Funk Laboratory of the Feinberg School of Medicine at Northwestern, the company said Wednesday.
Pressure BioSciences installs first 2 Barozyme high throughput systems, expects to ship next 3 in the coming weeks
Pressure BioSciences (OTCQB:PBIO) says it has installed its first two Barozyme HT-48 high throughput systems for independent evaluation and potential sale.
Pressure BioSciences posts 14% rise in Q3 products and services revenue, growth expected to continue
Pressure BioSciences (OTCQB:PBIO) said it continued to trim its operating loss as products and services revenue climbed 14 percent in the third quarter.
Pressure BioSciences' (OTCQB:PBIO) pressure cycling technology (PCT) has been used to develop a method to analyze thousands of proteins by mass spectrometry on small, needle biopsy samples for the first time, according to a presentation at the Human Proteome Organization World Congress in Spain held earlier this month.
ChroMedX (CSE:CHX) (OTC:MNLIF), which is working on two new medical devices that it says will change the face of in vitro diagnostics, said it has trademarked its patented HemoPalm technology in the US, which will be officially registered when it is released commercially.
Pressure BioSciences (OTCQB:PBIO) has expanded the reach of its products with a three-year exclusive distribution agreement with China's Powertech Technology, the company said Monday.
Investors interested in Amarin recently viewed
- Deltex Medical Group plc (AIM: DEMG) ....Save lives....Save bed days....Save money....
- SomnoMed (ASX: SOM) .
- HealthLinx (ASX: HTX) HealthLinx will be recognised as a leader in delivering diagnostic applicat
- African Medical Investments (AIM: AMEI) Capital Appreciation through Private Healthcare in Africa
- Regeneus Limited (ASX: RGS) .